Soricimed to investigate the potential benefit of its TRPV6 inhibitor, SOR-C13, in the treatment of COVID-19

BY      |     December 18, 2020

Soricimed Biopharma, a private Canadian clinical-stage company developing cancer drug candidates that target TRPV6 channel, announced that it will investigate the potential benefit of its cancer drug candidate, SOR-C13, in the treatment of COVID-19.

TRPV6 is a selective calcium channel present in high amounts on the surface of cancer solid-tumor cells and required for the growth, metastasis and resistance to programmed death.

SOR-C13, is a novel, short, synthetic peptide developed from the C-terminal region of soricidin, a proprietary 54 amino acid peptide, found in the saliva of the Northern Short-tailed Shrew. SOR-C13 binds with high affinity to TRPV6 and disrupts its function. SOR-C13 is designed to decrease calcium concentrations inside cancer cells to inhibit calcium-dependent cancer cell proliferation and induce the death of tumor cells overexpressing TRPV6.

Early modeling studies conducted by Soricimed demonstrated the ability of SOR-C13 to bind to the SARS-CoV-2 Spike protein, suggesting that it could potentially interfere with the interaction of the virus with the ACE2 receptor, and stop the entrance of SARS-CoV-2 into the cells (apparently in a TRPV6-independent manner).

Read the press release here.

Read more about Soricimed here.

Image by mattthewafflecat from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.